These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21187364)

  • 1. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
    Croce F; Vitello P; Dalla Pria A; Riva A; Galli M; Antinori S
    Int J STD AIDS; 2010 Nov; 21(11):783-5. PubMed ID: 21187364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe rhabdomyolysis associated with raltegravir use.
    Zembower TR; Gerzenshtein L; Coleman K; Palella FJ
    AIDS; 2008 Jul; 22(11):1382-4. PubMed ID: 18580624
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of rhabdomiolysis associated with raltegravir use.
    Dori L; Buonomini AR; Viscione M; Sarmati L; Andreoni M
    AIDS; 2010 Jan; 24(3):473-5. PubMed ID: 20087078
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Integrase inhibitor: raltegravir also as first line therapy].
    MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study.
    Calza L; Danese I; Colangeli V; Vandi G; Manfredi R; Girometti N; Borderi M; Appolloni L; Puggioli C; Viale P
    AIDS Res Hum Retroviruses; 2014 Dec; 30(12):1162-9. PubMed ID: 25369244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA notifications. Raltegravir indication extended for treatment-naive patients.
    AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
    [No Abstract]   [Full Text] [Related]  

  • 15. No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir.
    Baroncelli S; Mezzaroma I; Fantauzzi A; Galluzzo CM; Antoni AD; Vullo V; Francisci D; Ladisa N; Vivarelli A; Cirioni O; Sighinolfi L; Weimer LE; Fragola V; Fidanza R; Cara A; Palmisano L
    Antivir Ther; 2013; 18(3):321-7. PubMed ID: 23047152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of rhabdomyolysis during hospitalization for acute hepatitis A].
    Ann SH; An GH; Lee SY; Oak JH; Moon HI; Moon SK; Han NI; Lee YS
    Korean J Hepatol; 2009 Mar; 15(1):85-9. PubMed ID: 19346789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV
    Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine.
    Himmerich H; Ehrlinger M; Hackenberg M; Löhr B; Nickel T
    J Clin Psychopharmacol; 2006 Dec; 26(6):676-7. PubMed ID: 17110835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.